Eligard Kit
Product Images NDC 62935-303

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Eligard (NDC 62935-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tolmar Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 And Figure 2 (Eligard 1)

An instructional diagram labeled 'Syringe A Tray Contents' showing Syringe A and a separate Syringe B Plunger Rod. Syringe A includes a barrel and plunger assembled, while Syringe B Plunger Rod is displayed separately below it. The image is part of the ELIGARD kit by TOLMAR Inc. for subcutaneous use.*

FDA Label Image

Figure 14 And Figure 15 And Figure 16 And Figure 17 (Eligard 10)

An instructional image showing the preparation of ELIGARD Leuprolide Acetate kit for subcutaneous injection. It depicts two syringes labeled Syringe A and Syringe B being handled by a person wearing blue gloves, demonstrating combining or handling steps for the medication kit.*

FDA Label Image

153d1272-figure-12 (Eligard 11)

An instructional illustration showing a gloved hand assembling components of the ELIGARD kit. The image labels the needle, screw mechanism, and Syringe B, indicating where the needle should be attached by screwing it onto the syringe.*

FDA Label Image

Figure 18 (Eligard 12)

An instructional illustration showing hands wearing gloves assembling a syringe for ELIGARD. It depicts the step to pull back Syringe B, with arrows and labels indicating the motion and parts involved.*

FDA Label Image

Figure 19 (Eligard 13)

An instructional illustration showing a hand pinching the skin on an arm, demonstrating preparation for a subcutaneous injection.*

FDA Label Image

Figure 20 (Eligard 14)

An instructional illustration showing the correct technique for subcutaneous injection, depicting a syringe being held at a 90-degree angle to the skin. It demonstrates how to administer the injection with proper hand placement.*

FDA Label Image

Figure 21 (Eligard 15)

An instructional illustration showing a gloved hand holding a syringe with the needle cover being pushed off, indicated by an arrow and the word "Push." The image demonstrates how to remove the needle cover as part of the preparation or administration process.*

FDA Label Image

Figure 22 (Eligard 16)

An instructional diagram showing a gloved hand holding a syringe with a needle cover. The illustration shows an upward arrow and the word 'Push' indicating the removal or flipping of the needle cover before use. The image is related to the preparation or administration of a subcutaneous injection, consistent with drug kits like ELIGARD containing leuprolide acetate.*

FDA Label Image

Figure 23 (Eligard 17)

An instructional illustration showing a gloved hand holding a prefilled injector device for ELIGARD (Leuprolide Acetate) subcutaneous kit. The image highlights the step of pressing or activating the device, indicated by the word "Click."*

FDA Label Image

Figure 24 (Eligard 18)

An illustration showing a gloved hand holding a subcutaneous injection device with a visible protective cap and a caption "Click" indicating an action or step in the use of the device. The image suggests preparation or administration related to the ELIGARD Leuprolide Acetate kit.*

FDA Label Image

Figure 25 (Eligard 19)

Chemical structure diagram of Leuprolide Acetate, the active ingredient in ELIGARD. The image shows a molecular formula with detailed atomic connections typical for a peptide-based compound.*

FDA Label Image

Figure 3 And Figure 4 (Eligard 2)

Illustration showing the contents of ELIGARD kit's Syringe B tray, including a labeled syringe (Syringe B) and a detachable needle. The syringe is marked with measurement markings and has a blue plunger at one end.*

FDA Label Image

153d1272-figure-21 (Eligard 20)

A line graph depicting serum concentrations of Testosterone (ng/dL) and Leuprolide (ng/mL) over a study period of up to 3 months. The y-axis uses a logarithmic scale showing mean serum concentration with standard error. A horizontal line indicates the clinical castration threshold at ≤ 50 ng/dL of Testosterone.*

FDA Label Image

153d1272-figure-22 (Eligard 21)

A line graph depicting serum concentrations of testosterone (ng/dL) and leuprolide (ng/mL) over a 6-month study period in patients. The graph includes a clinical castration threshold line at 50 ng/dL for testosterone, showing changes in hormone levels with time during the study.*

FDA Label Image

153d1272-figure-23 (Eligard 22)

A line graph showing serum concentration (mean, SEM) of Testosterone and Leuprolide over an 8-month study period. The y-axis is logarithmic, measuring concentrations from 0.01 to 1000 ng/dL or ng/mL. A clinical castration threshold of 50 ng/dL is marked. Testosterone levels initially drop then stabilize below the threshold, while Leuprolide levels decline gradually after an initial peak.*

FDA Label Image

153d1272-figure-24 (Eligard 23)

A line graph showing serum concentrations over a 12-month study period for testosterone (ng/dL) and Leuprolide (ng/mL). The y-axis represents serum concentration on a logarithmic scale, and the x-axis shows study months from 0 to 12. A horizontal reference line indicates 50 ng/dL for clinical castration. Testosterone levels decline sharply and then stabilize below the reference, while Leuprolide levels fluctuate and generally decrease over time.*

FDA Label Image

153d1272-figure-25 (Eligard 24)

A line chart showing serum testosterone concentration (ng/dL) over 6 months post baseline for ELIGARD (Leuprolide Acetate). The graph includes six labeled injection points and depicts a sharp decline in testosterone levels shortly after baseline with stable low levels maintained through the following months.*

FDA Label Image

153d1272-figure-26 (Eligard 25)

A line graph depicting serum testosterone concentration (ng/dL) over time in months post baseline. The graph shows a rapid decline in testosterone levels shortly after injection #1, remaining low through injection #2 around month 3, followed by stable low levels up to month 6.*

FDA Label Image

153d1272-figure-27 (Eligard 26)

A line graph depicting serum testosterone concentration (ng/dL) over months post baseline, with two injection points marked. The graph shows a sharp decline in testosterone levels during the first month followed by stabilized low concentrations extending to 8 months.*

FDA Label Image

153d1272-figure-28 (Eligard 27)

A line graph showing serum testosterone concentration (ng/dL) over 12 months post baseline. The graph highlights a sharp decline in testosterone levels after Injection #1, followed by stable low levels maintained up to Injection #2 around month 6, with continued stability through month 12.*

FDA Label Image

Eligard 28

Packaging label for ELIGARD 7.5 mg kit containing leuprolide acetate for injectable suspension. The label indicates it is for subcutaneous injection, must be reconstituted before use, and is supplied by Tolmar Inc. Storage instructions specify refrigeration at 2 to 8°C (36 to 46°F). The label emphasizes the prescription-only status and includes NDC 62935-753-75 and a barcode.*

FDA Label Image

Eligard 29

ELIGARD 22.5 mg kit for subcutaneous injection, containing leuprolide acetate as an injectable suspension. The label states the dosage as 22.5 mg every 3 months. It includes preparation instructions, storage conditions (refrigerate 2 to 8°C), and the labeler as Tolmar Inc. The packaging displays product branding, NDC 62935-223-05, and regulatory information including Rx only status.*

FDA Label Image

Figure 5 (Eligard 3)

An instructional illustration showing a gloved hand pulling the plunger of Syringe B, labeled in the image, likely as part of the preparation or administration process for a subcutaneous injection.*

FDA Label Image

Eligard 30

ELIGARD 30 mg kit containing Leuprolide Acetate for injectable suspension, labeled for subcutaneous use every 4 months. The packaging includes instructions for reconstitution before use, storage recommendation at 2 to 8°C, and is labeled Rx only. It is manufactured and distributed by Tolmar Inc., Fort Collins, CO. The kit contains methoxypolyethylene glycol delivery system components and syringes for administration.*

FDA Label Image

Eligard 31

Packaging label for ELIGARD 45 mg subcutaneous injection kit by TOLMAR Inc., containing leuprolide acetate injectable suspension. The label highlights a 45 mg dose administered every 6 months, requires reconstitution before use, and specifies refrigeration between 2 to 8°C (36 to 46°F). The label includes storage instructions, contents details, and regulatory information including barcode and lot/expiration data.*

FDA Label Image

Figure 6 (Eligard 4)

An instructional illustration showing a gloved hand holding a syringe labeled 'Syringe B' while another hand is turning a screw at the end of the syringe. The image demonstrates the assembly or preparation step involving the syringe screw mechanism.*

FDA Label Image

Figure 7 (Eligard 5)

Illustration showing a gloved hand unscrewing the cap from Syringe A in the ELIGARD kit. The diagram highlights the step of preparing the syringe for use.*

FDA Label Image

Figure 8 And Figure 9 And Figure 10 (Eligard 6)

Instructional image showing a gloved hand pulling the cap off Syringe B from the ELIGARD kit containing Leuprolide Acetate for subcutaneous administration. The image demonstrates part of the preparation process using the drug kit by TOLMAR Inc.*

FDA Label Image

Figure 11 And Figure 12 And Figure 13 (Eligard 7)

Illustration showing two syringes labeled Syringe A and Syringe B connected by a screw mechanism. A person wearing blue gloves is holding and twisting the syringes together, demonstrating assembly or preparation of the device.*

FDA Label Image

Injection Belly (Eligard 8)

An instructional diagram showing two syringes, labeled Syringe A and Syringe B, held by gloved hands. An arrow between the syringes indicates to mix the contents for 45 seconds, demonstrating preparation steps for the ELIGARD Leuprolide Acetate subcutaneous injection kit.*

FDA Label Image

Injection Belly (Eligard 9)

An instructional illustration showing a two-syringe kit labeled Syringe A and Syringe B, with a gloved hand holding each syringe and an arrow indicating connection or mixing between Syringe A and Syringe B. The image appears to guide assembly or preparation steps for administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.